Searched over 200M research papers
6 papers analyzed
These studies suggest rosuvastatin generally reduces blood pressure and improves heart function.
6 papers analyzed
20 papers analyzed
Rosuvastatin is a statin medication primarily used to lower cholesterol levels and reduce the risk of cardiovascular disease. However, its effects on blood pressure (BP) have been a subject of research, with some studies suggesting potential antihypertensive benefits.
A meta-analysis of randomized controlled trials (RCTs) investigated the effects of rosuvastatin on systolic blood pressure (SBP) and diastolic blood pressure (DBP) in patients with hypertension. The analysis included five RCTs with a total of 507 patients. The findings indicated that rosuvastatin significantly reduced DBP by an average of 2.12 mmHg compared to the control group. Although there was a reduction in SBP by 2.27 mmHg, this change was not statistically significant. This suggests that rosuvastatin may have a modest antihypertensive effect, particularly on DBP.
In animal models, rosuvastatin has shown beneficial effects on blood pressure regulation. For instance, in spontaneously hypertensive rats, long-term rosuvastatin treatment was associated with a down-regulation of cytochrome P450 (CYP) 4A1 expression, which correlated with a blunted increase in blood pressure over time. Additionally, in dyslipidemic mice, rosuvastatin treatment improved nitric oxide (NO)-dependent endothelial function and reduced blood pressure variability, highlighting its potential to enhance vascular health.
Clinical trials have also explored the combined effects of rosuvastatin with other antihypertensive agents. A study involving a fixed-dose combination of rosuvastatin and amlodipine in patients with hypertension and dyslipidemia found significant reductions in both SBP and DBP after 8 weeks of treatment. The combination therapy was more effective in lowering blood pressure compared to monotherapy with either drug alone. Another trial demonstrated that combined therapy with rosuvastatin and antihypertensive agents significantly reduced cardiovascular events and blood pressure in individuals at intermediate risk for cardiovascular disease.
The current body of research suggests that rosuvastatin does not cause high blood pressure. On the contrary, it may have modest antihypertensive effects, particularly in reducing diastolic blood pressure. These effects are likely mediated through various mechanisms, including improved endothelial function and down-regulation of specific enzymes involved in blood pressure regulation. Therefore, rosuvastatin could be beneficial for patients with hypertension and dyslipidemia, contributing to better cardiovascular outcomes.
Most relevant research papers on this topic